Skip to content
value.today

Scorpion Therapeutics, Inc.

Total raised
$297 M
3 rounds on record
Latest round
$126 M
Jul 2024
First round on record
Apr 2020
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Scorpion Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2024$126 MNo. 3$50 to $250 million

Scorpion Therapeutics, Inc.: Raise no. 3, Jul 2024

Investors in this round

38 investors had bought by the notice of Jul 16, 2024: 38 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Scorpion Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$126 M of $150 M offered; $24 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adam Friedman · Executive Officer, Director
  • Amanda Valentino · Executive Officer
  • Andrew Fedder · Executive Officer
  • Brian Piper · Executive Officer
  • Darrin Stuart · Executive Officer
  • Erica Jackson · Executive Officer
  • Mark Chao · Executive Officer
  • Arjun Goyal · Director
  • Jean-Francois Formela · Director
  • Jeffrey Albers · Director
  • Keith Flaherty · Director
  • Oleg Nodelman · Director
  • Otello Stampacchia · Director
  • Saurabh Saha · Director
  • Shelley Chu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Adam Friedman, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 16, 2024. Read the notice at the SEC.

equitySEC
Nov 2020$147 MNo. 2$50 to $250 million

Scorpion Therapeutics, Inc.: Raise no. 2, Nov 2020

Investors in this round

22 investors had bought by the notice of Dec 7, 2020: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Scorpion Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$147 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gary Glick · Executive Officer, Director
  • Peter Joseph Campisi, Jr. · Executive Officer
  • Arjun Joseph Goyal · Director
  • Jean-Francois Joseph Formela · Director
  • Keith Joseph Flaherty · Director
  • Otello Joseph Stampacchia · Director
  • Shelley Joseph Chu · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter Joseph Campisi, Jr., Secretary. Source: SEC Form D, newest notice filed Dec 7, 2020. Read the notice at the SEC.

equitySEC
Apr 2020$25 MNo. 1$10 to $50 million

Scorpion Therapeutics, Inc.: Raise no. 1, Apr 2020

Investors in this round

11 investors had bought by the notice of May 19, 2020: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Scorpion Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gary Glick · Executive Officer, Director
  • Peter Joseph Campisi, Jr. · Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter Joseph Campisi, Jr., Secretary and General Counsel. Source: SEC Form D, newest notice filed May 19, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Scorpion Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2024).

    SEC Form D · Jul 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2024

That is all the official record says: Scorpion Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: its website does not allow automated readers.

Investors#

4 named in official filings. Open an investor to see everything it has backed.

Investors in Scorpion Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Select Biotechnology PortfolioFund or asset manager$4 Mheldnot statedHolds shares (fund report, May 2026)SEC Form N-PORT
Fidelity Growth Company FundFund or asset manager$2 Mheldnot statedHolds shares (fund report, May 2026)SEC Form N-PORT
Fidelity Growth Company K6 FundFund or asset manager$1 Mheldnot statedHolds shares (fund report, May 2026)SEC Form N-PORT
Fidelity Series Growth Company FundFund or asset manager$0 Mheldnot statedHolds shares (fund report, May 2026)SEC Form N-PORT

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 38 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Scorpion Therapeutics, Inc.
NameRoleNamed in
Adam FriedmanExecutive officerJul 2024
Amanda ValentinoExecutive officerJul 2024
Andrew FedderExecutive officerJul 2024
Brian PiperExecutive officerJul 2024
Darrin StuartExecutive officerJul 2024
Erica JacksonExecutive officerJul 2024
Mark ChaoExecutive officerJul 2024
Gary GlickExecutive officerDec 2020
Peter Joseph Campisi, Jr.Executive officerDec 2020
Adam FriedmanDirectorJul 2024
Arjun GoyalDirectorJul 2024
Jean-Francois FormelaDirectorJul 2024
Jeffrey AlbersDirectorJul 2024
Keith FlahertyDirectorJul 2024
Oleg NodelmanDirectorJul 2024
Otello StampacchiaDirectorJul 2024
Saurabh SahaDirectorJul 2024
Shelley ChuDirectorJul 2024
Arjun Joseph GoyalDirectorDec 2020
Gary GlickDirectorDec 2020
Jean-Francois Joseph FormelaDirectorDec 2020
Keith Joseph FlahertyDirectorDec 2020
Otello Joseph StampacchiaDirectorDec 2020
Shelley Joseph ChuDirectorDec 2020

About

Company in Boston, United States.